BACKGROUND:With the introduction of highly active antiretroviral therapy (HAART) the outlook of HIV/AIDS has changed from a killer disease to a treatable chronic infectious one. However HAART is associated with some metabolic disorders some of which are now being seen in people living with HIV/ AIDS (PLWHA) accessing care from our centre. OBJECTIVE: To determine the prevalence and pattern of dyslipidaemia and dysglycaemia amongst Nigerian HIV/AIDS patients on HAART. METHODS: PLWHA who were regular on ART for at least three months and had pre-treatment CD4 + count, fasting lipid and glucose profiles were grouped into two treatment regimens: protease inhibitor, (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI). Pre and post-exposure metabolic and nonmetabolic variables were compared for each regimen as well as within regimen comparison of the differences between post exposure metabolic variables. RESULTS: Three hundred and twenty-seven patients; [male=134 (41%), female=193 (59%)] met the study criteria in the two groups: PI = 94(29%) and NNRTI= 233(71%). The pretreatment metabolic changes in both groups (PI vs. NNRTI) were low HDL-C; 29(31%) vs.77 (33%), followed by hypertriglyceridaemia; 16(17%) vs.38 (16%) and hypercholesterolaemia; 6(6%) vs.10 (4%). After exposure to two different HAART regimens hypertriglyceridaemia and hypercholesterolaemia became more prevalent especially with Pi based therapy than NNRTI; 74(79%) vs. 108(54%) and 58(51%) vs.72(31%) respectively. These relative higher risks of a PI containing regimen to induce hypertriglyceridaemia and hypercholesterolaemia were about three times more than that of NNRTI, both risks were statistically significant; p = 0.0003 and p = 0.0001. 29 (31%) vs.77 (33%), suivie par l'hypertriglycéridémie, 16 (17%) vs.38 (16%) et l'hypercholestérolémie , 6 (6%) vs.10 (4%)
RĂSUMĂ CONTEXTE: Avec l'introduction du traitement antirĂ©troviral hautement actif (HAART) l'Ă©volution du VIH
MĂTHODES: les PVVIH qui ont Ă©tĂ© rĂ©guliĂšrement sous ARV pendant au moins trois mois et a prĂ©-traitement CD4 + count, le jeĂ»ne de lipides et de glucose profils ont Ă©tĂ© regroupĂ©s en deux rĂ©gimes de traitement: inhibiteur de protĂ©ase (IP) ou non-nuclĂ©osidiques de la transcriptase inverse inhibiteur (INNTI). PrĂ© et post-exposition mĂ©taboliques et non-mĂ©taboliques variables ont Ă©tĂ© comparĂ©s pour chaque rĂ©gime, ainsi que dans le rĂ©gime comparaison des diffĂ©rences entre post-exposition mĂ©taboliques variables.
RĂSULTATS: Trois cent vingt-sept patients, [les hommes = 134 (41%), les femmes = 193 (59%)] a rencontrĂ© l'Ă©tude des critĂšres dans les deux groupes: PI = 94 (29%) et INNTI = 233 (71% ). Le prĂ©traitement des changements mĂ©taboliques dans les deux groupes (c. INNTI IP) sont faibles